DOI: https://doi.org/10.22141/2224-0551.13.2.2018.129554

Peroxisomal biogenesis disorders in Zellweger syndrome spectrum: diagnosis, monitoring and treatment according to the recommendations of the Global Foundation for Peroxisomal Disorders

M.A. Gonchar, G.R. Muratov, O.L. Logvinova, E.M. Pushkar, E.P. Pomazunovskaya, E.V. Omelchenko, N.V. Shulga, I.M. Galdina, A.S. Zubko, N.V. Strebul

Abstract


The article deals with the modern principles for the diagnosis and treatment of peroxisomal biogenesis disorders of Zellweger syndrome spectrum according to the recommendations of the Global Foundation for Peroxisomal Disorders 2016. The authors presented the clinical features of these diseases. The lesions of the nervous, bone, urinary, endocrine, sensory systems and tooth enamel are characteristic signs of the disease. Our own clinical observation on the disturbances of oxidation of very long chain fatty acids in an infant is considered separately. Section of Zellweger spectrum disorders diagnosis is based on world standards for disease diagnosis and includes markers of very long-chain fatty acid β-oxidation, as well as α-oxidation by pristanic and phytanic acids, metabolism of pipecolic acid and other peroxisomal dysfunctions. The final diagnosis of peroxisomal biogenesis disorders in Zellweger syndrome spectrum at the present stage is established by the genetic testing method, ­using the sequencing techniques of the new generation for the PEX genes. The severity of neurological disorders and the progressive course of the disease, as well as emergence of the possibility of treating X-linked adrenoleukodystrophy opened the prospects of screening for X-linked adrenoleukodystrophy based on a combination of liquid chromatography and tandem mass spectrometry to detect the elevated levels of very long-chain fatty acids in newborns in blood spots. Clinical monitoring since diagnosis was established includes correction of initial disturbances and revealing disease symptoms, which appear later.

Keywords


peroxisomal diseases; Zellweger syndrome; children; diagnosis; treatment

References


Braverman NE, D'Agostino MD, Maclean GE. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev. 2013;17(3):187-96. doi: 10.1002/ddrr.1113.

Zellweger H, Maertens P, Superneau D, Wertelecki W. History of the cerebrohepatorenal syndrome of Zellweger and other peroxisomal disorders. South Med J. 1988 Mar;81(3):357-64. PMID: 2450404.

Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006 Dec;1763(12):1733-48. doi: 10.1016/j.bbamcr.2006.09.010.

Yik WY, Steinberg SJ, Moser AB, Moser HW, Hacia JG. Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders. Hum Mutat. 2009 Mar;30(3):E467-80. doi: 10.1002/humu.20932.

Ebberink MS, Mooijer PA, Gootjes J, Koster J, Wanders RJ, Waterham HR. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat. 2011 Jan;32(1):59-69. doi: 10.1002/humu.21388.

Ebberink MS, Csanyi B, Chong WK, et al. Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene. J Med Genet. 2010 Sep;47(9):608-15. doi: 10.1136/jmg.2009.074302.

Régal L, Ebberink MS, Goemans N, et al. Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol. 2010 Aug;68(2):259-63. doi: 10.1002/ana.22035.

Sevin C, Ferdinandusse S, Waterham HR, Wanders RJ, Aubourg P. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J Rare Dis. 2011 Mar 10;6:8. doi: 10.1186/1750-1172-6-8.

Majewski J, Wang Z, Lopez I, et al. A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing. J Med Genet. 2011 Sep;48(9):593-6. doi: 10.1136/jmedgenet-2011-100288.

Ratbi I, Falkenberg KD, Sommen M, et al. Heimler syndrome is caused by hypomorphic mutations in the peroxisomebiogenesis genes PEX1 and PEX6. Am J Hum Genet. 2015 Oct 1;97(4):535-45. doi: 10.1016/j.ajhg.2015.08.011.

Poll-The BT, Gootjes J, Duran M, et al. Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients. Am J Med Genet A. 2004 May 1;126A(4):333-8. doi: 10.1002/ajmg.a.20664.

Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006;75:295-332. doi: 10.1146/annurev.biochem.74.082803.133329.

Steinberg S, Jones R, Tiffany C, Moser A. Investigational methods for peroxisomal disorder. Curr Protoc Hum Genet. 2008 Jul;Chapter 17:Unit 17.6. doi: 10.1002/0471142905.hg1706s58.

Stradomska TJ, Bachański M, Pawłowska J, Syczewska M, Stolarczyk A, Tylki-Szymańska A. The impact of a ketogenic diet and liver dysfunction on serum very long-chain fatty acids levels. Lipids. 2013 Apr;48(4):405-9. doi: 10.1007/s11745-013-3761-y.

Theda C, Woody RC, Naidu S, Moser AB, Moser HW. Increased very long chain fatty acids in patients on a ketogenic diet: a cause of diagnostic confusion. J Pediatr. 1993 May;122(5 Pt 1):724-6.

Peduto A, Baumgartner MR, Verhoeven NM, et al. Hyperpipecolic acidaemia: a diagnostic tool for peroxisomal disorders. Mol Genet Metab. 2004 Jul;82(3):224-30. doi: 10.1016/j.ymgme.2004.04.010.

Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta. 2012 Sep;1822(9):1430-41. doi: 10.1016/j.bbadis.2012.04.006.

Steinberg SJ, Snowden A, Braverman NE, et al. A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts. J Inherit Metab Dis. 2009 Feb;32(1):109-19. doi: 10.1007/s10545-008-0969-8.

Krause C, Rosewich H, Gärtner J. Rational diagnostic strategy for Zellweger syndrome spectrum patients. Eur J Hum Genet. 2009 Jun;17(6):741-8. doi: 10.1038/ejhg.2008.252.

Ferdinandusse S, Denis S, Hogenhout EM, et al. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat. 2007 Sep;28(9):904-12. doi: 10.1002/humu.20535.

Lieber DS, Hershman SG, Slate NG, et al. Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency. BMC Med Genet. 2014 Mar 6;15:30. doi: 10.1186/1471-2350-15-30.

Haugarvoll K, Johansson S, Tzoulis C, et al. MRI characterisation of adult onset alphamethylacyl-coA racemase deficiency diagnosed by exome sequencing. Orphanet J Rare Dis. 2013 Jan 3;8:1. doi: 10.1186/1750-1172-8-1.

Wanders RJA, Waterham HR, Leroy BP. Refsum Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 2006. 1993-2018 pp.

Wierzbicki А.S. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review. Biochem Soc Trans. 2007 Nov;35(Pt 5):881-6. doi: 10.1042/BST0350881.

Ferdinandusse S, Kostopoulos P, Denis S, et al. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet. 2006 Jun;78(6):1046-52. doi: 10.1086/503921.

Levesque S, Morin C, Guay SP, et al. A founder mutation in the PEX6 gene is responsible for increased incidence of Zellweger syndrome in a French Canadian population. BMC Med Genet. 2012 Aug 15;13:72. doi: 10.1186/1471-2350-13-72.

Sun Y, Wang L, Wei X, et al. Analysis of a Chinese pedigree with Zellweger syndrome reveals a novel PEX1 mutation by next-generation sequencing. Clin Chim Acta. 2013 Feb 18;417:57-61. doi: 10.1016/j.cca.2012.12.005.

Buchert RH, Tawamie H, Smith C, et al. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am J Hum Genet. 2014 Nov 6;95(5):602-10. doi: 10.1016/j.ajhg.2014.10.003.

Hubbard WC, Moser AB, Liu AC, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC–MS/MS) method. Mol Genet Metab. 2009 Jul;97(3):212-20. doi: 10.1016/j.ymgme.2009.03.010.

Vogel BH, Bradley SE, Adams DJ, et al. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab. 2015 Apr;114(4):599-603. doi: 10.1016/j.ymgme.2015.02.002.

Al-Sayed M, Al-Hassan S, Rashed M, Qeba M, Coskun S. Preimplantation genetic diagnosis for Zellweger syndrome. Fertil Steril. 2007 Jun;87(6):1468.e1-3. doi: 10.1016/j.fertnstert.2006.09.014.

Lee PR, Raymond GV. Child neurology: Zellweger syndrome. Neurology. 2013 May 14;80(20):e207-10. doi: 10.1212/WNL.0b013e3182929f8e.

Barkovich AJ, Peck WW. MR of Zellweger syndrome. AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1163-70.

Van Duyn MA, Moser AE, Brown FR 3rd, Sacktor N, Liu A, Moser HW. The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. Am J Clin Nutr. 1984 Aug;40(2):277-84. doi: 10.1093/ajcn/40.2.277.

Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy. N Engl J Med. 1993 Sep 9;329(11):745-52. doi: 10.1056/NEJM199309093291101.

Rizzo WB, Leshner RT, Odone A, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology. 1989 Nov;39(11):1415-22.

Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci. 1991;13(4-5):274-9. doi: 10.1159/000112173.

Egge H, Murawski U, György P, Zilliken F. Minor constituents of human milk (I) identification of cyclohexaneundecanoic acid and phytanic acid in human milk fat by a combination gas chromatograph-mass spectrometer. FEBS Lett. 1969 Feb;2(4):255-258.

Watkins PA, Moser AB, Toomer CB, et al. Identification of differences in human and great ape phytanic acid metabolism that could influence gene expression profiles and physiological functions. BMC Physiol. 2010 Oct 8;10:19. doi: 10.1186/1472-6793-10-19.

Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology. 2010 Aug 31;75(9):826-30. doi: 10.1212/WNL.0b013e3181f07061.

Clayton P.T. Inborn errors of bile acid metabolism. J Inherit Metab Dis. 1991;14(4):478-96.

Theil AC, Schutgens RB, Wanders RJ, Heymans HS. Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients. Eur J Pediatr. 1992 Feb;151(2):117-20.

Broomfield SJ, Bruce IA, Henderson L, Ramsden RT, Green KM. Cochlear implantation in children with syndromic deafness. Int J Pediatr Otorhinolaryngol. 2013 Aug;77(8):1312-6. doi: 10.1016/j.ijporl.2013.05.022.

Wilson GN, Holmes RG, Custer J, et al. Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am J Med Genet. 1986 May;24(1):69-82. doi: 10.1002/ajmg.1320240109.

Hittner HM, Kretzer FL, Mehta RS. Zellweger syndrome. Lenticular opacities indicating carrier status and lens abnormalities characteristic of homozygotes. Arch Ophthalmol. 1981 Nov;99(11):1977-82.

Maeda K, Kimura A, Yamato Y, et al. Oral bile Acid treatment in two Japanese patients with Zellweger syndrome. J Pediatr Gastroenterol Nutr. 2002 Aug;35(2):227-30.

Behringer M, Gruetzner S, McCourt M, Mester J. Effects of weight-bearing activities on bone mineral content and density in children and adolescents: a meta-analysis. J Bone Miner Res. 2014 Feb;29(2):467-78. doi: 10.1002/jbmr.2036.




Copyright (c) 2018 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта